STOCK TITAN

Cvrx, Inc. Stock Price, News & Analysis

CVRX Nasdaq

Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.

CVRx, Inc. (NASDAQ: CVRX) is a commercial-stage medical device company whose news flow centers on its Barostim neuromodulation platform for cardiovascular disease, particularly heart failure. The company regularly issues press releases and investor updates detailing financial performance, operational metrics and developments related to Barostim.

Readers of CVRX news can expect recurring coverage of quarterly and annual financial and operating results, including revenue trends, gross margin, operating expenses, cash and cash equivalents, and the growth of active implanting centers and sales territories in the U.S. and Europe. The company also reports on reimbursement milestones, such as the transition of Barostim procedures to Category I CPT codes and CMS decisions affecting outpatient payment classifications and physician fee levels.

Another key theme in CVRx news is clinical and regulatory progress. The company has highlighted FDA actions such as the Breakthrough Device designation for Barostim and the grant of an Investigational Device Exemption for the BENEFIT-HF trial, a randomized controlled study designed to evaluate Barostim’s impact on outcomes in an expanded heart failure population. Updates on applications to the Centers for Medicare & Medicaid Services for trial coverage and other reimbursement-related developments are also part of the company’s announcements.

CVRx news releases frequently mention participation in major healthcare and investor conferences, where the management team presents the company’s strategy and Barostim-related data to the investment community. For investors and observers following CVRX, this news page provides a centralized view of earnings releases, reimbursement and coding changes, clinical trial plans, financing arrangements, and conference appearances linked to the company’s heart failure therapy platform.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.75%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.34%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.21%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.3%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.49%
Tags
conferences earnings
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
conferences

FAQ

What is the current stock price of Cvrx (CVRX)?

The current stock price of Cvrx (CVRX) is $6.96 as of February 3, 2026.

What is the market cap of Cvrx (CVRX)?

The market cap of Cvrx (CVRX) is approximately 186.6M.
Cvrx, Inc.

Nasdaq:CVRX

CVRX Rankings

CVRX Stock Data

186.62M
23.85M
4.31%
67.77%
7.31%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MINNEAPOLIS

CVRX RSS Feed